Loading...
Loading...
CARM| Name | Value |
|---|---|
| Revenues | 4.3M |
| Cost of Revenue | 2.1M |
| Gross Profit | 2.2M |
| Operating Expense | 24.7M |
| Operating I/L | -22.4M |
| Other Income/Expense | 1.3M |
| Interest Income | 1.3M |
| Pretax | -21.2M |
| Income Tax Expense | -0.2M |
| Net Income/Loss | -21.0M |
Carisma Therapeutics, Inc. is a biopharmaceutical company specializing in the development of chimeric antigen receptor (CAR) macrophages for the treatment of solid tumors. Their innovative solutions harness the innate and adaptive immune response, utilizing advancements in macrophage biology, CAR engineering, and adoptive cellular therapy for treating human diseases. The company's strategic collaboration with Moderna Inc. enhances its position in the market, driving revenue through the development and commercialization of these cutting-edge therapies.
